TRIZ Lies

G. L. Filkovsky, TRIZ Master,
Bonaire, Netherlands Antilles
e-mail:genady@diverecord.com

This December issue of The TRIZ Journal was used by the editor herself, Ellen Domb, to lie about using TRIZ. This time it was about "Using TRIZ to Accelerate Technology Transfer in the Pharmaceutical Industry". Every statement in the article about using TRIZ is false.

In the abstract: "Case studies demonstrate that TRIZ can solve these problems, and speed the progress of new pharmaceuticals to market." This is a lie. No case studied in the article using TRIZ solved a problem. In all cases, the problems were solved without TRIZ. TRIZ did not speed the progress of new pharmaceuticals to market.

"The TRIZ concepts ... are applied to the improvement of testing, reduction of toxicity, and scale up for production in several areas of the pharmaceutical industry." This is a lie. No TRIZ concepts were applied to the improvement of testing, reduction of toxicity, and scale up for production in cases studied in the article. The TRIZ concepts are applied only by Ellen Domb to tag the solutions retrospectively.

"These solutions demonstrate the use of 2 of the 40 principles for problem solving." No, these solutions do not demonstrate the use of these or other TRIZ principles, since the solutions have been achieved without them. The principles are imposed by Ellen Domb on existing solutions.

"A very simple TRIZ solution does not solve the problem of foam creation, but it makes foam not cause problems for downstream processes: ... extract the liquid from the bottom of the tank, to get pure liquid without any foam." This is a misnomer. It is not a "TRIZ solution": it was developed without TRIZ.

"Considerable improvement in uniformity has been achieved by electro statically depositing the material on a continuous web of edible material. ... The 'Beginner TRIZ' method from the 40 principles ... was used." None of the 40 principles was used to develop this technology.

In conclusion, "This collection of case studies from technology transfer in the pharmaceutical industry is designed to demonstrate that the skills of beginner level TRIZ can make substantial contributions to the problem solving that is necessary to move a new drug along the exhaustive pathway from basic research to clinical research to full commercialization." Not true. This collection of case studies is designed to create a fake impression that TRIZ was actually used in pharmaceutical industry.

"For pharmaceutical audiences, this may answer the question: 'Does TRIZ work in my environment ?'" Yes, this may answer. The answer here should be "No, it does not work."